Equity Overview
Price & Market Data
Price: $5.07
Daily Change: -$0.09 / 1.78%
Daily Range: $4.90 - $5.42
Market Cap: $13,541,319
Daily Volume: 24,379
Performance Metrics
1 Week: 4.84%
1 Month: -3.71%
3 Months: 14.09%
6 Months: -45.67%
1 Year: -71.30%
YTD: -43.80%
Company Details
Employees: 43
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.